Since its establishment, the company has always been driven by scientific and technological innovation, and under the dedicated efforts of the professional research and development team led by returned Doctor, covering multiple disciplines and various categories, it has formed a high-end characteristic apis product system in the treatment fields of anti-tumor drugs, antiviral drugs, cardiovascular drugs and Alzheimer's drugs。The company has established provincial and municipal innovative R&D platform carriers such as "Jiangsu Provincial Molecular Precision Targeted Drug Engineering Technology Research Center for Major Diseases", "Jiangsu Graduate Student Workstation", "Suzhou Lixin Pharmaceutical anti-tumor Drug Engineering Technology Research Center" and "Suzhou Enterprise Technology Center"，With Soochow University, Soochow University of Science and Technology, Shanghai University of Engineering Science and Technology, Soochow Vocational University and Jiangnan University through the establishment of joint laboratories, joint practice bases and other forms to achieve industry-university-research integration。Continuous process optimization and quality improvement, the products have passed the NMPA technical review and GMP compliance inspection, and some key products have passed the US FDA and EU EDQM field audit。